Cannabis Effects on Antiretroviral Therapy Pharmacokinetics and Neurotoxicity
This study will address whether cannabis affects antiretroviral therapy (ART) drug concentrations, mood, and thinking. The project will have two phases. Phase 1 is an observational study, in which 120 people will be assessed to evaluate the effects of chronic cannabis use on ART drug concentrations, mood, and thinking. In Phase 2, the study will administer cannabis (or placebo) to 40 people to examine its acute effects on ART drug concentrations.
People with human immunodeficiency virus (HIV) commonly use cannabis but whether cannabis affects the antiretroviral therapy (ART) that treats HIV is not well known. Cannabis can inhibit the activity of enzymes that metabolize and eliminate ART drugs from the body, which could result in higher concentrations of ART drugs in the body. Cannabis may also affect the distribution of ART drugs into the brain, which could have both beneficial (e.g., better HIV control) and detrimental (e.g., toxicity) effects. The effects of cannabis may are likely influenced by factors like how much is used (e.g., light vs. heavy use) and the route of use (e.g., smoked vs. ingested). This study will address whether cannabis affects ART concentrations in blood and cerebrospinal fluid as well as mood, and thinking. The project will have two phases. Phase 1 is an observational study, in which 120 people will be assessed once to evaluate the effects of chronic cannabis use on ART drug concentrations, mood, and thinking. In Phase 2, the study will administer cannabis (or placebo) to 40 people to examine its acute effects on ART drug concentrations.
HIV Cannabis Use Neurotoxicity Syndromes Marijuana Abuse THC Cannabis CBD Cannabis
You can join if…
Open to people ages 18 years and up
for All Visits:
- Age 18 or older;
- Capacity to provide informed consent;
- Presence of HIV infection by a standard diagnostic test;
- On a stable ART regimen for at least 3 months;
- Taking an ART drug that is metabolized by either cytochrome p450 (CYP) isozymes or by uridine 5'-diphospho-glucuronosyltransferase (UGT) isozymes; and
- Willing to abstain from cannabis for at least 24 hours prior to the Phase 1 assessment.
Additional Inclusion Criteria for participation in Phase 2 (interventional):
- Treatment with dolutegravir;
- Use of cannabis in the past two years without a severe adverse reaction (e.g., disorientation, paranoia, or hallucinations). The two-year cutoff is to ensure exposure to modern cannabis, which is more likely to match the drug concentrations administered in this study;
- Willing to refrain from driving or operating heavy machinery after the visit; and
- Willing to abstain from cannabis for at least 48 hours prior to the cannabis administration visits.
You CAN'T join if...
for All Visits:
- Traumatic brain injury, including head injury with loss of consciousness for greater than 30 minutes or resulting in neurologic complications;
- Dementia, including Alzheimer's disease;
- History of stroke with residual neurologic sequelae;
- History of seizure disorder with a seizure in the past year;
- Severe psychiatric disorder (e.g., schizophrenia) that might make the person's participation in the study unsafe;
- Substance or alcohol use disorder in the past 12 months;
- Contraindications to lumbar puncture for those consenting to lumbar puncture (e.g., coagulopathy).
Additional Exclusion Criteria for participation in the cannabis administration visits:
- Younger than 21 years (due to safety of cannabis in children and adolescents);
- Respiratory condition that would be exacerbated by inhaling vaporized cannabis (e.g., asthma or chronic obstructive pulmonary disease) or limited lung capacity that would prevent the individual from performing the Foltin puff procedure;
- History of cardiovascular disease, including myocardial infarction;
- Uncontrolled hypertension with systolic blood pressure greater than 160 mm Hg or a diastolic blood pressure greater than 100 mm Hg prior to study product administration;
- Resting pulse greater than 100 beats per minute prior to study product administration;
- Pregnancy as determined by a human chorionic gonadotropin urine test, women who are lactating, or unwillingness to prevent pregnancy during the cannabis administration portion of the study (using birth control in women of child-bearing age). Acceptable methods of birth control are: oral contraceptive pills, diaphragm, condom, progestin implant, intrauterine contraceptive device, sterilization, etc;
- Active opportunistic infection or malignancy requiring treatment;
- CD4+ T-cell count less than 200 cells/µL;
- Estimated glomerular filtration rate < 40 mL/minute, indicative of renal dysfunction;
- . Hepatic transaminases > 2 times the upper limit of normal;
- . Current severe depressive symptoms (BDI-II score ≥ 31) or suicidal ideation;
- . Known sensitivity to acetaminophen (the probe for UGT activity);
- . Current use of substances that could have adverse interactions with acetaminophen or cannabis (e.g., grapefruit juice).
- Ucsd Hnrp-Cmcr
accepting new patients
San Diego California 92103 United States
Lead Scientist at UCSD
- Scott Letendre, MD
Professor in Residence, Medicine. Authored (or co-authored) 285 research publications.
- accepting new patients
- Start Date
- Completion Date
- University of California, San Diego
- Phase 2
- Study Type
- Last Updated
Please contact me about this study
We will not share your information with anyone other than the team in charge of this study. Submitting your contact information does not obligate you to participate in research.
The study team should get back to you in a few business days.